PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

Diabetes 40

Diabetes Biosimilars 40

PharmaShots

MARCH 9, 2023

Education: She is a Post Graduate Research Fellow in Gastroenterology and Immunology from Stanford University School of Medicine. Other Affiliations: Alison works as a visiting researcher at Imperial College's Institute of Biomedical Engineering. Education: Alison has a Doctor Philosophy (Ph.D.),

Clinical Pharmacology 40

Clinical Pharmacology Immunity Immunization Pharmaceutical Companies 40

European Pharmaceutical Review

NOVEMBER 10, 2022

Advanced light microscopy techniques have emerged as a foundation of biomedical research, capable of visualising cellular functions at very high resolution whilst being minimally invasive to the cells or tissues of interest. This will help researchers to understand how formulation can improve cellular uptake to be more efficient.

Labelling 96

Labelling Compounding 96